

News release via Canada NewsWire, Vancouver 604-669-7764

Attention Business/Financial Editors:  
Welichem Filed Quarterly Report for Period Ended August 31, 2007

BURNABY, BC, Oct. 30 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced today that the Company filed its first quarter financials and MD & A. The net loss for the 3-month period ended August 31, 2007 were \$593,104 (2006 - \$866,701) and 1 cent per share (2006 - 3 cents per share).

Detailed information is available on SEDAR website ([www.sedar.com](http://www.sedar.com)).

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer.

ON BEHALF OF THE BOARD

York Yingping Guo  
President & Chief Executive Officer

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.

%SEDAR: 00021386E

/For further information: York Yingping Guo, Tel.: (604) 432-1703, Email: [yorkguo@welichem.com](mailto:yorkguo@welichem.com); Yan Chen, Business Development Manager, Tel.: (604) 432-1703, Email: [investors@welichem.com](mailto:investors@welichem.com)/  
(WBI.)

CO: Welichem Biotech Inc.

CNW 14:22e 30-OCT-07